Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Published:2017-05 Issue:5 Volume:18 Page:611-622
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ascierto Paolo A,Del Vecchio Michele,Robert Caroline,Mackiewicz Andrzej,Chiarion-Sileni Vanna,Arance Ana,Lebbé Céleste,Bastholt Lars,Hamid Omid,Rutkowski Piotr,McNeil Catriona,Garbe Claus,Loquai Carmen,Dreno Brigitte,Thomas Luc,Grob Jean-Jacques,Liszkay Gabriella,Nyakas Marta,Gutzmer Ralf,Pikiel Joanna,Grange Florent,Hoeller Christoph,Ferraresi Virginia,Smylie Michael,Schadendorf Dirk,Mortier Laurent,Svane Inge Marie,Hennicken Delphine,Qureshi Anila,Maio Michele

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy;Hoos;Semin Oncol,2010

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

4. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial;Maio;J Clin Oncol,2015

5. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

Cited by 422 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melanoma Brain Metastasis;Hematology/Oncology Clinics of North America;2024-10

2. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors;Journal of Clinical Oncology;2024-09-01

3. Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module;European Journal of Cancer;2024-08

4. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024;Journal of the National Comprehensive Cancer Network;2024-07

5. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review;Cancers;2024-05-28